Recent advances in CAR-T cell engineering

Recent advances in CAR-T cell engineering

Abstract Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for relapsed or refractory tumors, particularly for hematological malignancies. Although the initially approved anti-CD19 CAR-T therapy has produced impressive outcomes, setbacks such as high relapse rates...

Full description

Bibliographic Details
Main Authors: Ruihao Huang, Xiaoping Li, Yundi He, Wen Zhu, Lei Gao, Yao Liu, Li Gao, Qin Wen, Jiang F. Zhong, Cheng Zhang, Xi Zhang
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Journal of Hematology & Oncology
Subjects:
CAR-T cell therapy
Hematological malignancies
Immune therapy
Online Access:http://link.springer.com/article/10.1186/s13045-020-00910-5

Internet

http://link.springer.com/article/10.1186/s13045-020-00910-5

Similar Items